<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03864939</url>
  </required_header>
  <id_info>
    <org_study_id>HAM01</org_study_id>
    <nct_id>NCT03864939</nct_id>
  </id_info>
  <brief_title>Application of Dried Human Amnion Graft to Improve Postprostatectomy Incontinence and Potency</brief_title>
  <official_title>Randomized Pilot Study to Improve Postprostatectomy Incontinence and Potency by Application of Dried Human Amnion Graft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Centre for Assessment and Evaluation of Innovative Techniques in Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Centre for Assessment and Evaluation of Innovative Techniques in Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators present a randomized trial of patients undergoing placement of dehydrated
      human amnion membrane (dHAM) around the neurovascular bundle (NVB) and vesicourethral
      anastomosis (VUA) during radical retropubic prostatectomy (RRP) in a tertiary center in
      Germany.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients suffer under incontinence and impotence after RRP, improving techniques and studies
      are missing. The human amniotic membrane includes growth factors and unique immune tolerance
      which can improve tissue regeneration. The preliminary studies could prove the potential
      value of dHAM in the reconstruction of the urinary tract and nerve protection. The
      investigators initially present a randomized trial to improve postoperative continence and
      potency of patients undergoing placement of dehydrated human amnion membrane (dHAM) around
      the neurovascular bundle (NVB) and vesicourethral anastomosis (VUA) during RRP for the
      treatment of prostate cancer. RRP is performed in a standardized way by one experienced
      surgeon. The patients are randomized 1:1 to dHAM vs. placebo and blinded during the study
      period. The primary outcome is a postoperative continence measure as 24hrs pad test up to
      12mos postoperatively. Secondary outcomes are potency, insufficiency of VUA, postoperative
      complications and biochemical recurrence. Using the T-test with an alpha of 0.05 and a power
      of 80% and expecting a drop-out of 20% of the patients, an adjusted sample size per arm of
      164 patients is required.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients are blinded during the study period.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in urine loss</measure>
    <time_frame>From baseline (1 week after surgery) to 3 weeks after surgery</time_frame>
    <description>Urine loss is assessed by 24 hrs pad-test (in gram)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in urine loss</measure>
    <time_frame>From baseline (1 week after surgery) to 6 weeks after surgery</time_frame>
    <description>Urine loss is assessed by 24 hrs pad-test (in gram)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in urine loss</measure>
    <time_frame>From baseline (1 week after surgery) to 3 months after surgery</time_frame>
    <description>Urine loss is assessed by 24 hrs pad-test (in gram)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in urine loss</measure>
    <time_frame>From baseline (1 week after surgery) to 12 months after surgery</time_frame>
    <description>Urine loss is assessed by 24 hrs pad-test (in gram)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in erectile function (EF)</measure>
    <time_frame>From baseline (4 weeks before surgery) to 6 weeks after surgery</time_frame>
    <description>EF is assessed by IIEF-5 (the International Index of Erectile Function) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erectile function (EF)</measure>
    <time_frame>From baseline (4 weeks before surgery) to 3 months after surgery</time_frame>
    <description>EF is assessed by IIEF-5 (the International Index of Erectile Function) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erectile function (EF)</measure>
    <time_frame>From baseline (4 weeks before surgery) to 12 months after surgery</time_frame>
    <description>EF is assessed by IIEF-5 (the International Index of Erectile Function) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative catheter removal</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Time of postoperative catheter removal (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>perioperative, at 6 weeks, 3 months and 12 months</time_frame>
    <description>Complications are assessed according to Clavien-Dindo classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical recurrence</measure>
    <time_frame>at 6 weeks, 3 months and 12 months</time_frame>
    <description>Measurement of prostate-specific antigen (PSA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">328</enrollment>
  <condition>Continence</condition>
  <condition>Potency</condition>
  <condition>Complication</condition>
  <condition>Biochemical Recurrence</condition>
  <arm_group>
    <arm_group_label>dHAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dHAM wrap is placed during RRP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A standard RRP is performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dHAM</intervention_name>
    <description>A dehydrated human amnion membrane (dHAM, 1x3cm) is placed around the neurovascular bundle (NVB) on the left and right side and vesicourethral anastomosis (VUA) during radical retropubic prostatectomy (RRP).</description>
    <arm_group_label>dHAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No dHAM</intervention_name>
    <description>A standard radical retropubic prostatectomy (RRP) without dHAM is performed (Walsh, 2005).</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with localized prostate cancer

          -  indication for radical prostatectomy

          -  no other treatment of prostate cancer

          -  availability to informed consent

        Exclusion Criteria:

          -  preoperative incontinence (24hrs pad-test)

          -  preoperative erectile dysfunction (IIEF-5 &lt; 20)

          -  metastasized or locally advanced prostate cancer in preoperative assessment

          -  previous radiation of pelvis

          -  previous prostate cancer therapy

          -  psychiatric disease

          -  participation at another study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitri Barski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Lukas Hospital Neuss</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dimitri Barski, PhD</last_name>
    <phone>004921318882401</phone>
    <email>dbarski@lukasneuss.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Otto, Prof</last_name>
    <phone>004921318882401</phone>
    <email>totto@lukasneuss.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Urology, Lukas Hospital</name>
      <address>
        <city>Neuss</city>
        <zip>40464</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Dimitri Barski, PhD</last_name>
      <phone>004921318882401</phone>
      <email>dbarski@lukasneuss.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.ics.org/Publications/ICI_3/v1.pdf/chap13.pdf</url>
    <description>Abrams P, Cardozo L, Khoury S, Wein A. 2005. Incontinence Basics&amp; Evaluation, 3rd International Consultation on Incontinence. Chapter 13: Imaging and other Investigations.</description>
  </link>
  <reference>
    <citation>Abrams P, Andersson KE, Apostolidis A, Birder L, Bliss D, Brubaker L, Cardozo L, Castro-Diaz D, O'Connell PR, Cottenden A, Cotterill N, de Ridder D, Dmochowski R, Dumoulin C, Fader M, Fry C, Goldman H, Hanno P, Homma Y, Khullar V, Maher C, Milsom I, Newman D, Nijman RJM, Rademakers K, Robinson D, Rosier P, Rovner E, Salvatore S, Takeda M, Wagg A, Wagner T, Wein A; members of the committees. 6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: EVALUATION AND TREATMENT OF URINARY INCONTINENCE, PELVIC ORGAN PROLAPSE AND FAECAL INCONTINENCE. Neurourol Urodyn. 2018 Sep;37(7):2271-2272. doi: 10.1002/nau.23551. Epub 2018 Aug 14.</citation>
    <PMID>30106223</PMID>
  </reference>
  <reference>
    <citation>Asimakopoulos AD, Miano R, Galfano A, Bocciardi AM, Vespasiani G, Spera E, Gaston R. Retzius-sparing robot-assisted laparoscopic radical prostatectomy: Critical appraisal of the anatomic landmarks for a complete intrafascial approach. Clin Anat. 2015 Oct;28(7):896-902. doi: 10.1002/ca.22576. Epub 2015 Jul 21.</citation>
    <PMID>26194970</PMID>
  </reference>
  <reference>
    <citation>Barski D, Gerullis H, Ecke T, Varga G, Boros M, Pintelon I, Timmermans JP, Otto T. Human Amniotic Membrane Is Not Suitable for the Grafting of Colon Lesions and Prevention of Adhesions in a Xenograft Rat Model. Surg Innov. 2017 Aug;24(4):313-320. doi: 10.1177/1553350617709828. Epub 2017 May 26.</citation>
    <PMID>28548553</PMID>
  </reference>
  <reference>
    <citation>Barski D, Gerullis H, Ecke T, Varga G, Boros M, Pintelon I, Timmermans JP, Otto T. Human amniotic membrane dressing for the treatment of an infected wound due to an entero-cutaneous fistula: Case report. Int J Surg Case Rep. 2018;51:11-13. doi: 10.1016/j.ijscr.2018.08.015. Epub 2018 Aug 13.</citation>
    <PMID>30130666</PMID>
  </reference>
  <reference>
    <citation>Barski D, Gerullis H, Ecke T, Varga G, Boros M, Pintelon I, Timmermans JP, Winter A, Bagner JW, Otto T. Repair of a vesico-vaginal fistula with amniotic membrane - Step 1 of the IDEAL recommendations of surgical innovation. Cent European J Urol. 2015;68(4):459-61. doi: 10.5173/ceju.2015.683. Epub 2015 Nov 13.</citation>
    <PMID>26855802</PMID>
  </reference>
  <reference>
    <citation>Barski D, Gerullis H, Ecke T, Yang J, Varga G, Boros M, Pintelon I, Timmermans JP, Otto T. Bladder Reconstruction with Human Amniotic Membrane in a Xenograft Rat Model: A Preclinical Study. Int J Med Sci. 2017 Mar 11;14(4):310-318. doi: 10.7150/ijms.18127. eCollection 2017.</citation>
    <PMID>28553162</PMID>
  </reference>
  <reference>
    <citation>Capogrosso P, Salonia A, Briganti A, Montorsi F. Postprostatectomy Erectile Dysfunction: A Review. World J Mens Health. 2016 Aug;34(2):73-88. doi: 10.5534/wjmh.2016.34.2.73. Epub 2016 Aug 23. Review.</citation>
    <PMID>27574591</PMID>
  </reference>
  <reference>
    <citation>D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):969-74.</citation>
    <PMID>9749478</PMID>
  </reference>
  <reference>
    <citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13.</citation>
    <PMID>15273542</PMID>
  </reference>
  <reference>
    <citation>Lemke A, Ferguson J, Gross K, Penzenstadler C, Bradl M, Mayer RL, Gerner C, Redl H, Wolbank S. Transplantation of human amnion prevents recurring adhesions and ameliorates fibrosis in a rat model of sciatic nerve scarring. Acta Biomater. 2018 Jan 15;66:335-349. doi: 10.1016/j.actbio.2017.11.042. Epub 2017 Nov 28.</citation>
    <PMID>29191510</PMID>
  </reference>
  <reference>
    <citation>Ogaya-Pinies G, Kadakia Y, Palayapalayam-Ganapathi H, Woodlief T, Jenson C, Syed J, Patel V. Use of Scaffolding Tissue Biografts To Bolster Vesicourethral Anastomosis During Salvage Robot-assisted Prostatectomy Reduces Leak Rates and Catheter Times. Eur Urol. 2018 Jul;74(1):92-98. doi: 10.1016/j.eururo.2016.10.004. Epub 2016 Oct 14.</citation>
    <PMID>27751731</PMID>
  </reference>
  <reference>
    <citation>Ogaya-Pinies G, Palayapalam-Ganapathi H, Rogers T, Hernandez-Cardona E, Rocco B, Coelho RF, Jenson C, Patel VR. Can dehydrated human amnion/chorion membrane accelerate the return to potency after a nerve-sparing robotic-assisted radical prostatectomy? Propensity score-matched analysis. J Robot Surg. 2018 Jun;12(2):235-243. doi: 10.1007/s11701-017-0719-8. Epub 2017 Jun 27.</citation>
    <PMID>28656504</PMID>
  </reference>
  <reference>
    <citation>Patel VR, Samavedi S, Bates AS, Kumar A, Coelho R, Rocco B, Palmer K. Dehydrated Human Amnion/Chorion Membrane Allograft Nerve Wrap Around the Prostatic Neurovascular Bundle Accelerates Early Return to Continence and Potency Following Robot-assisted Radical Prostatectomy: Propensity Score-matched Analysis. Eur Urol. 2015 Jun;67(6):977-980. doi: 10.1016/j.eururo.2015.01.012. Epub 2015 Jan 19.</citation>
    <PMID>25613153</PMID>
  </reference>
  <reference>
    <citation>Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 Jun;49(6):822-30.</citation>
    <PMID>9187685</PMID>
  </reference>
  <reference>
    <citation>Walsh PC. Re: Anatomical radical retropubic prostatectomy: detailed description of the surgical technique. J Urol. 2005 Jan;173(1):324.</citation>
    <PMID>15592108</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 3, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lukas-Krankenhaus GmbH</investigator_affiliation>
    <investigator_full_name>Dimitri Barski</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

